Today’s Trademark – InflaRx

The trademark of INFLARX is owned by InflaRx GmbH and was registered in USTPO bearing registration number 5682819 on February 26th, 2019.

InflaRx N.V., founded in 2007 in Jena, Germany, is a clinical-stage biopharmaceutical company specializing in the development of monoclonal antibodies targeting the complement system’s C5a protein. Their lead product, vilobelimab, is an anti-C5a monoclonal antibody designed to treat severe inflammatory conditions. Vilobelimab has undergone Phase III clinical trials for hidradenitis suppurativa and is being explored for other conditions, including ANCA-associated vasculitis and pyoderma gangraenosum. Additionally, InflaRx is developing INF904, an oral small molecule aimed at chronic inflammatory and autoimmune diseases. The company is publicly traded on NASDAQ under the ticker IFRX.